ERBB2 and triple-negative breast carcinoma: Molecular characteristics revealed two cases (0.5%) of ER-/PR+, 24 cases (6.2%) of ER+/PR-, 102 cases (26%) of HER2/neu+, 81 cases (21%) of triple-negative breast cancer, and 122 cases (31.4%) of Ki67 positivity.